Biopharmx (NYSEAMERICAN:BPMX) Sees Large Volume Increase

Biopharmx Corp (NYSEAMERICAN:BPMX) saw strong trading volume on Tuesday . 1,178,400 shares traded hands during mid-day trading, an increase of 95% from the previous session’s volume of 603,176 shares.The stock last traded at $0.39 and had previously closed at $0.37.

Separately, Maxim Group set a $1.00 price target on Biopharmx and gave the stock a “buy” rating in a research note on Monday, September 9th.

Biopharmx (NYSEAMERICAN:BPMX) last posted its quarterly earnings data on Monday, September 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12.

In related news, major shareholder Vivo Capital Viii, Llc sold 327,870 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $1.02, for a total transaction of $334,427.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Biopharmx stock. Deutsche Bank AG raised its position in Biopharmx Corp (NYSEAMERICAN:BPMX) by 1,256.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 549,973 shares of the biotechnology company’s stock after purchasing an additional 509,430 shares during the quarter. Deutsche Bank AG owned 0.25% of Biopharmx worth $59,000 at the end of the most recent quarter.

Biopharmx Company Profile (NYSEAMERICAN:BPMX)

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Article: How does a margin account work?

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.